U.S. Markets closed

MediciNova, Inc. (MNOV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.95-0.10 (-1.65%)
At close: 4:00PM EDT
People also watch
OPXACYTKTTHIGTXILXRX
Interactive chart
Previous Close6.05
Open6.10
Bid4.15 x 100
Ask10.00 x 500
Day's Range5.88 - 6.10
52 Week Range4.85 - 8.00
Volume33,550
Avg. Volume40,076
Market Cap205.52M
Beta0.14
PE Ratio (TTM)-19.26
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research3 months ago

    MNOV: MN-166 Making Progress in Numerous Indications…

    There have been a number of recent announcements regarding MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. - On February 7, 2017, MediciNova, Inc. (MNOV) announced that an abstract regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, which is taking place from Apr. 22-28, 2017 in Boston, Massachusetts. - On December 20, 2016, MediciNova announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 for the treatment of ALS.

  • Zacks Small Cap Research5 months ago

    MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion

    On December 19, 2016, MediciNova, Inc. (MNOV) announced that the Data and Safety Monitoring Board (DSMB) for the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) reviewed the results of the interim efficacy analysis and recommended to the National Institute of Neurological Diseases and Stroke (NINDS) that the trial should continue as planned, to which the NINDS has agreed. Thus, the fact that the DSMB recommended that the trial continue as planned is indicative that there is at least a positive trend in the direction of efficacy for MN-166. If there was no trend in favor of MN-166, the trial would have been stopped for futility.

  • MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
    Capital Cube5 months ago

    MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016

    Categories: Yahoo Finance Get free summary analysis MediciNova, Inc. reports financial results for the quarter ended September 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -2.84 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. MNOV-US‘s earnings and ... Read more (Read more...)